How to reach us: Austria, Czech Republic, France, Germany, Italy, Poland, Spain, Switzerland, Turkey and Great Britain TO TOP Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014 2021 Download Report MORE DETAILS Corporate news & press releases 05.11.21 MagForce AG: MagForce USA, Inc. has Received FDA’s Approval to Proceed with Stage 2B with the Final Protocol of the Pivotal U.S. Study for the Focal Ablation of Prostate Cancer with the NanoTherm Therapy System 28.10.21 MagForce AG Publishes Financial Results for H1/2021 and Operative Highlights 13.10.21 MagForce AG: MagForce USA, Inc. has Received FDA’s Conditions for Approval of the Final Protocol of the Pivotal U.S. Study for the Focal Ablation of Prostate Cancer with the NanoTherm Therapy System OTHER NEWS Events & financial calendar OTHER EVENTS Financial and business reports Transparent and extensive: Annual financial statements, management report and much more at a glance. 2021 Half Year Report Download PDF 2020 Annual Report 2020 Download PDF 2020 Half-year Report Download PDF VIEW ALL Research reports Analyst opinions – assessments. Institute Analyst Update Recommendation Stifel (formerly Mainfirst) Dr. Marcus Wieprecht 01. October 2021 Buy Hauck & Aufhäuser Alexander Galitsa 09. November 2021 Buy GBC AG Investment Research Cosmin Filker, Marcel Goldman 18. October 2021 Buy Edison Research Dr. John Priestner, Dr. Sean Conroy 10. November 2021 Buy VIEW ALL Annual general meetings All documents concerning the Annual General Meeting of MagForce AG. The annual general meeting of MagForce AG will take place on August 12, 2021 as a virtual general meeting VIDEO SPEECH DR. BEN LIPPS, CEO 2021 Voting Results (German) Download PDF 2021 Presentation of the Annual General Meeting 2021 Download PDF 2021 Addition to the Agenda Download PDF VIEW ALL Shareholder letters Current interim reports to our shareholders, with supplementary reporting on recent developments and achievements. 2021 October Letter to shareholders Download PDF June 2021 Letter to shareholders Download PDF 2020 October Letter to shareholders Download PDF VIEW ALL Mandatory publications Ad hoc annoucements and other mandatory publications of MagForce AG. 2021 05. November Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014 Download PDF 10. March 2021 Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014 Download PDF 08. February 2021 Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014 Download PDF VIEW ALL Media Center Further information and press material for download in our Media Centre. Browse through numerous interesting videos, photos and documents. VIEW MEDIA CENTER Registration for investor and press news Newsletter for Investors and Press News Subscribe to our email newsletter and stay informed about the latest MagForce publications. FIRST NAME* LAST NAME* E-MAIL* COMPANY NAME I have read and accepted the Privacy Policy. Contact Permission: I consent to MagForce AG contacting me for information purposes. Your data will be handled strictly and confidentially and will not be shared with third parties. Contact us Do you still have questions? We would be happy to inform you about our company and current developments in our innovative method of treating cancer. We would be happy to answer press and investor inquiries by phone or email. Investor Relations & Public Relations Barbara von Frankenberg Vice President Communications & Investor Relations 00 49 30 308380 77 bfrankenberg@magforce.com Press releases Don’t miss a thing: news, dates and current press releases. Share price information Current price data of the stock exchange XETRA. Yes, I agree to the processing and use of my personal data in accordance with the Privacy Policy for the purpose of contacting. This website uses Google Analytics to improve future content. Please click here to set an opt‑out‑Cookie if you do not want Google Analytics to track your browsing habits. OK Important Pages Our Therapy For Patients Financial Reports Contact News & Events 05.11.21 MagForce AG: MagForce USA, Inc. has Received FDA’s Approval to Proceed with Stage 2B with the Final Protocol of the Pivotal U.S. Study for the Focal Ablation of Prostate Cancer with the NanoTherm Therapy System © 2021 MagForce AG, The Nanomedicine Company Privacy Policy Imprint